Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome.

Abstract:

:Advanced-stage mycosis fungoides and Sezary syndrome (MF/SS) have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT), particularly using a reduced-intensity conditioning (RIC) regimen, is a promising treatment for advanced-stage MF/SS. We performed RIC-HSCT in nine patients with advanced MF/SS. With a median follow-up period of 954 days after HSCT, the estimated 3-year overall survival was 85.7% (95% confidence interval, 33.4-97.9%) with no non-relapse mortality. Five patients relapsed after RIC-HSCT; however, in four patients whose relapse was detected only from the skin, persistent complete response was achieved in one patient, and the disease was manageable in other three patients by the tapering of immunosuppressants and donor lymphocyte infusion, suggesting that graft-versus-lymphoma effect and 'down-staging' effect from advanced stage to early stage by HSCT improve the prognosis of advanced-stage MF/SS. These results suggest that RIC-HSCT is an effective treatment for advanced MF/SS.

journal_name

Hematol Oncol

journal_title

Hematological oncology

authors

Shiratori S,Fujimoto K,Nishimura M,Hatanaka KC,Kosugi-Kanaya M,Okada K,Sugita J,Shigematsu A,Hashimoto D,Endo T,Kondo T,Abe R,Hashino S,Matsuno Y,Shimizu H,Teshima T

doi

10.1002/hon.2162

subject

Has Abstract

pub_date

2016-03-01 00:00:00

pages

9-16

issue

1

eissn

0278-0232

issn

1099-1069

journal_volume

34

pub_type

杂志文章
  • On point in primary CNS lymphoma.

    abstract::Primary CNS lymphoma (PCNSL) is an aggressive brain tumor that represents a significant challenge both to elucidate its biological pathogenesis as well as to develop definitive precision medicines with minimal collateral toxicity. We highlight the key issues in diagnosis and treatment and focus on emerging technologie...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2761

    authors: Tsang M,Cleveland J,Rubenstein JL

    更新日期:2020-12-01 00:00:00

  • Long-term results of treatment of patients with follicular lymphomas.

    abstract::The management of patients with follicular lymphoma is controversial, particularly in those with follicular small cleaved cell (FSCC) or nodular poorly differentiated lymphoma (NPDL). Some advocate no treatment until symptoms arise, while others prefer to treat with intensive combination regimens and others with singl...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900050207

    authors: Kalter S,Holmes L,Cabanillas F

    更新日期:1987-04-01 00:00:00

  • Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-κB signalling instead of B-cell receptor signalling.

    abstract::Post-transplant lymphoproliferative disorders (PTLD) are a major problem in transplant medicine. So far, the insights into pathogenesis and potentially druggable pathways in PTLD remain scarce. We investigated a cohort of PTLD patients, consisting of both polymorphic (n = 3) and monomorphic (n = 19) B-cell lymphoproli...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2280

    authors: Menter T,Dickenmann M,Juskevicius D,Steiger J,Dirnhofer S,Tzankov A

    更新日期:2017-06-01 00:00:00

  • BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.

    abstract::Langerhans cell histiocytosis (LCH) is a proliferative disease of CD1a+ /CD207+ dendritic cells. Recurrent BRAFV600E and MAP2K1 mutations have been reported in LCH. To investigate the relationship among the mutation, clinical findings, and differentiation status of LCH, respectively, we studied 97 cases of LCH by usin...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2344

    authors: Zeng K,Ohshima K,Liu Y,Zhang W,Wang L,Fan L,Li M,Li X,Wang Z,Guo S,Yan Q,Guo Y

    更新日期:2017-12-01 00:00:00

  • Analysis of immunoglobulin heavy and light chain variable genes in post-transplant lymphoproliferative disorders.

    abstract::Post-transplant lymphoproliferative disorders (PTLD) derive from antigen-experienced B-cells and represent a major complication of solid organ transplantation. We characterized usage, mutation frequency and mutation pattern of immunoglobulin variable (IGV) gene rearrangements in 50 PTLD (polymorphic PTLD, n=10; diffus...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.791

    authors: Capello D,Cerri M,Muti G,Lucioni M,Oreste P,Gloghini A,Berra E,Deambrogi C,Franceschetti S,Rossi D,Alabiso O,Morra E,Rambaldi A,Carbone A,Paulli M,Gaidano G

    更新日期:2006-12-01 00:00:00

  • Angiocentric T-cell lymphoma of the nose, paranasal sinuses and hard palate.

    abstract::Sixty-five cases of malignant lymphoma of the nose, paranasal sinuses and hard palate were retrospectively analysed to identify the presence or absence of angiocentric lesions. We observed that the 23 patients with angiocentric lesions had a worse prognosis with a shorter duration of response and also a shorter durati...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900100303

    authors: Aviles A,Rodriguez L,Guzman R,Talavera A,Garcia EL,Diaz-Maqueo JC

    更新日期:1992-05-01 00:00:00

  • Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.

    abstract::Continuous administration of amphotericin B deoxycholate over 24 hours (24 h-D-AmB) is better tolerated than rapid infusions. However, toxicity and outcome have not been assessed in a homogenous patient population with acute myeloid leukaemia (AML). We retrospectively analysed renal function and outcome in all adult p...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2500

    authors: Rothenbühler C,Held U,Manz MG,Schanz U,Gerber B

    更新日期:2018-04-01 00:00:00

  • Intensified therapy followed by autologous stem-cell transplantation (ASCT) versus conventional therapy as first-line treatment of follicular lymphoma: a meta-analysis.

    abstract::There are two different international standards for the treatment of follicular lymphoma (FL): intensified therapy followed by autologous stem-cell transplantation (ASCT) and conventional therapy in the first-line setting. However, their role remains unclear. Our aim was to define the treatment effect of intensified t...

    journal_title:Hematological oncology

    pub_type: 杂志文章,meta分析

    doi:10.1002/hon.2015

    authors: Wang B,Ren C,Zhang W,Ma X,Xia B,Sheng Z

    更新日期:2013-03-01 00:00:00

  • Inducible lymphokine-activated killer (LAK) cell activity in the peripheral blood of patients with relapsed/refractory non-Hodgkin's lymphoma (NHL).

    abstract::Therapy with recombinant interleukin-2 (rIL-2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non-Hodgkin's lymphoma (NHL) have been treated with rIL-2. The present study sought to determine if peripheral blood mononuclear cells (PBM) from patien...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900080205

    authors: Zamkoff KW,Watman NP,Duggan DB,Poiesz BJ,Gottlieb AJ

    更新日期:1990-03-01 00:00:00

  • Cost-effectiveness of the introduction of specialized oral care with laser therapy in hematopoietic stem cell transplantation.

    abstract::Oral mucositis (OM) is one of the side effects of hematopoietic stem cell transplantation (HSCT), resulting in major morbidity. The aim of this study was to determine the cost-effectiveness of the introduction of a specialized oral care program including laser therapy in the care of patients receiving HSCT with regard...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2050

    authors: Bezinelli LM,de Paula Eduardo F,da Graça Lopes RM,Biazevic MG,de Paula Eduardo C,Correa L,Hamerschlak N,Michel-Crosato E

    更新日期:2014-03-01 00:00:00

  • Antisense therapy for lymphomas.

    abstract::The potential ability of antisense oligonucleotides to downregulate the expression of oncogenes involved in lymphoma, with minimal toxicity can be achieved. The possibility of combining antisense therapy such as BCL-2 antisense with chemotherapy will probably provide an interesting means of overcoming tumour cell resi...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/(sici)1099-1069(199702)15:1<3::aid-hon583>

    authors: Cotter FE

    更新日期:1997-02-01 00:00:00

  • The more basic isoform of eEF1A relates to tumour cell phenotype and is modulated by hyper-proliferative/differentiating stimuli in normal lymphocytes and CCRF-CEM T-lymphoblasts.

    abstract::The elongation factor 1A proteins (eEF1A1/A2) are known to play a role in tumours. We previously found that a more basic isoform of eEF1A (MBI-eEF1A) is present in the cytoskeletal/nuclear-enriched extracts of CCRF-CEM T-lymphoblasts but not in those of normal lymphocytes. To obtain deeper knowledge about MBI-eEF1A bi...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2022

    authors: Scaggiante B,Dapas B,Pozzato G,Grassi G

    更新日期:2013-06-01 00:00:00

  • Auer rods in the acute myeloid leukemias: frequency and methods of demonstration.

    abstract::One hundred and twenty-five cases of acute myeloid leukemia (AML) were reviewed for the presence of Auer rods by two peroxidase methods. The percentage of Auer rods recognized by Wright-Giemsa (WG) staining was 20.8% but three times higher by peroxidase staining techniques using either benzidine base as a substrate (P...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900050306

    authors: Jain NC,Cox C,Bennett JM

    更新日期:1987-07-01 00:00:00

  • Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy.

    abstract::We verified whether early resistance to treatment can be predicted in a subset of patients with very favourable, early stage Hodgkin lymphoma, treated with VBM (vinblastine, bleomycin and methotrexate) chemotherapy and involved-field radiotherapy, an effective combination with very low early and late toxicity. The rel...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2035

    authors: Gobbi PG,Bergonzi M,Bassi E,Merli F,Coriani C,Federico M

    更新日期:2013-09-01 00:00:00

  • Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma.

    abstract::Our aim was to evaluate whether quality of life (QOL) scores at diagnosis predict survival among patients with aggressive lymphoma. Newly diagnosed lymphoma patients were prospectively enrolled within 9 months of diagnosis in the University of Iowa/Mayo Clinic SPORE and systematically followed for event-free and overa...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.2522

    authors: Thompson CA,Yost KJ,Maurer MJ,Allmer C,Farooq U,Habermann TM,Inwards DJ,Macon WR,Link BK,Rosenthal AC,Cerhan JR

    更新日期:2018-12-01 00:00:00

  • Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.

    abstract::There have been some reports on a possible role of azacytidine (AZA) in the treatment of accelerated/blastic phase evolved from Philadelphia-negative myeloproliferative neoplasms (MPN-AP/BP), but results are conflicting. In this study, we analyzed a cohort of 39 patients with MPN-AP/BP treated frontline with AZA at th...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2635

    authors: Andriani A,Elli E,Trapè G,Villivà N,Fianchi L,Di Veroli A,Niscola P,Centra A,Anaclerico B,Montanaro G,Martini V,Aroldi A,Carmosino I,Voso MT,Breccia M,Montanaro M,Foà R,Latagliata R

    更新日期:2019-08-01 00:00:00

  • Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-Real-world data from the Medical University of Vienna.

    abstract::Based on results of two pilot trials, lenalidomide (LEN) was found to be active and safe as monotherapy and showed an increased response rate of 80% in combination with rituximab (R) for patients with mucosa-associated lymphoid tissue (MALT) lymphoma. While initial results were promising, there are currently no data o...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2647

    authors: Kiesewetter B,Lamm W,Neuper O,Mayerhoefer ME,Simonitsch-Klupp I,Raderer M

    更新日期:2019-10-01 00:00:00

  • Relationship between myeloblasts and cluster-forming cells in acute non-lymphocytic leukemia.

    abstract::The relationship between myeloblast-like cells and cluster-forming cells detected by growth in agar has been studied in 22 untreated patients with acute non-lymphocytic leukemia by means of comparing data for 3H-TdR labelling of myeloblast-like cells and 3H-TdR suiciding of cluster-forming cells. The fraction of myelo...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900020210

    authors: Gustavsson A,Olofsson T,Olsson I

    更新日期:1984-04-01 00:00:00

  • Protein kinase C isozyme expression in human leukemia-lymphoma cell lines--an immunocytochemical study.

    abstract::There have been an increasing number of reports describing a pivotal role for phosphorylation in cellular responses for cell differentiation and proliferation. We examined an immunocytochemical expression of protein kinase C(PKC) isozymes (type I, II, and III) in 22 leukemia-lymphoma cell lines. Of these cell lines, 2...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900100602

    authors: Hojo H,Morimura Y,Abe M,Tominaga K,Nozawa Y,Nakamura N,Ono N,Tasaki K,Yamaguchi Y,Suzuki S

    更新日期:1992-11-01 00:00:00

  • Residual mediastinal widening following therapy in Hodgkin's disease.

    abstract::The chest radiograms (CXR) of 102 patients with Hodgkin's disease presenting with mediastinal involvement at diagnosis were reviewed to assess the incidence and relevance of residual mediastinal abnormalities after therapy. All patients had completed planned treatment and had no evidence of persisting extramediastinum...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900080303

    authors: Orlandi E,Lazzarino M,Brusamolino E,Caldera D,Morra E,Dore R,Di Giulio G,Bernasconi C

    更新日期:1990-05-01 00:00:00

  • The new World Health Organization classification of lymphomas: the past, the present and the future.

    abstract::The REAL Classification of lymphomas, proposed in 1994, represents a new paradigm in lymphoma classification, consisting of a list of biologic entities defined by clinicopathologic and immunogenetic features. The non-Hodgkin's lymphomas comprise precursor lymphoblastic and mature cell neoplasms of B, T or putative nat...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.660

    authors: Chan JK

    更新日期:2001-12-01 00:00:00

  • Smoking and subsequent risk of acute myeloid leukaemia: A pooled analysis of 9 cohort studies in Japan.

    abstract::Smoking has been identified as a significant risk factor for acute myeloid leukaemia (AML). However, epidemiological evidence for the effect of smoking on the risk of AML among Asians is scarce. Here, we investigated the impact of smoking habits on the risk of AML by conducting a pooled analysis of 9 population-based ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2457

    authors: Ugai T,Matsuo K,Oze I,Ito H,Wakai K,Wada K,Nagata C,Nakayama T,Liu R,Kitamura Y,Tamakoshi A,Tsuji I,Sugawara Y,Sawada N,Sadakane A,Tanaka K,Mizoue T,Inoue M,Tsugane S,Shimazu T,Research Group for the Development a

    更新日期:2018-02-01 00:00:00

  • First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.

    abstract::During the formation of the Philadelphia (Ph) chromosome, in the majority of chronic myelogenous leukemia (CML) patients, the chromosome 22 breakpoint is located in the major breakpoint cluster region of the BCR gene (M-bcr). Minor and micro breakpoint cluster regions (m-bcr with e1a2 transcript and micro-bcr with e19...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.822

    authors: Andrikovics H,Nahajevszky S,Szilvási A,Bors A,Adám E,Kozma A,Kajtár B,Barta A,Poros A,Tordai A

    更新日期:2007-09-01 00:00:00

  • Acute myeloid leukaemia: expression of MYC protein and its association with cytogenetic risk profile and overall survival.

    abstract::Acute myeloid leukaemia (AML) is a clinically aggressive disease with marked genetic heterogeneity. Cytogenetic abnormalities provide the basis for risk stratification into clinically favourable, intermediate, and unfavourable groups. There are additional genetic mutations, which further influence the prognosis of pat...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2279

    authors: Mughal MK,Akhter A,Street L,Pournazari P,Shabani-Rad MT,Mansoor A

    更新日期:2017-09-01 00:00:00

  • Delayed platelet recovery after allogeneic hematopoietic stem cell transplantation: Association with chronic graft-versus-host disease and survival outcome.

    abstract::Delayed platelet recovery (DPR) despite prompt neutrophil engraftment is frequently observed after allogeneic hematopoietic stem cell transplantation (HSCT). However, few studies have evaluated the risk factors and long-term outcome. Therefore, we retrospectively analysed 219 adult patients who underwent their first a...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2427

    authors: Akahoshi Y,Kimura SI,Gomyo A,Hayakawa J,Tamaki M,Harada N,Kusuda M,Kameda K,Ugai T,Wada H,Ishihara Y,Kawamura K,Sakamoto K,Sato M,Terasako-Saito K,Kikuchi M,Nakasone H,Kako S,Kanda Y

    更新日期:2018-02-01 00:00:00

  • Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells.

    abstract::In order to develop an effective immunotherapy for hematological malignancies, we investigated the applicability of class II transactivator (CIITA), which had been demonstrated to regulate the expression of MHC class II (MHC-II) by assembling the transcription factors of MHC-II molecules, for immunotherapy by potentia...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/(sici)1099-1069(199912)17:4<149::aid-hon64

    authors: Liu A,Takahashi M,Toba K,Zheng Z,Hashimoto S,Nikkuni K,Furukawa T,Koike T,Aizawa Y

    更新日期:1999-12-01 00:00:00

  • Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.

    abstract::In 2009, the four laboratories of the Fondazione Italiana Linfomi (FIL) minimal residual disease (MRD) Network started a collaborative effort to harmonize and standardize their methodologies at the national level, performing quality control (QC) rounds for follicular lymphoma (FL) and mantle cell lymphoma (MCL) MRD as...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2652

    authors: Della Starza I,Cavalli M,De Novi LA,Genuardi E,Mantoan B,Drandi D,Barbero D,Ciabatti E,Grassi S,Gazzola A,Mannu C,Agostinelli C,Piccaluga PP,Bomben R,Degan M,Gattei V,Guarini A,Foà R,Galimberti S,Ladetto M,Ferrero

    更新日期:2019-10-01 00:00:00

  • Conventional and high-dose daunorubicin and idarubicin in acute myeloid leukaemia remission induction treatment: a mixed treatment comparison meta-analysis of 7258 patients.

    abstract::Previous meta-analyses suggested that acute myeloid leukaemia induction regimens containing idarubicin (IDA) or high-dose daunorubicin (HDD) induce higher rates of complete remission (CR) than conventional-dose daunorubicin (CDD), with a possible benefit in overall survival. However, robust comparisons between these r...

    journal_title:Hematological oncology

    pub_type: 杂志文章,meta分析

    doi:10.1002/hon.2173

    authors: Sekine L,Morais VD,Lima KM,Onsten TG,Ziegelmann PK,Ribeiro RA

    更新日期:2015-12-01 00:00:00

  • A pilot study of ChlOPhEPP-B--a weekly regimen for patients with untreated advanced or recurrent Hodgkin's disease.

    abstract::Twenty-five patients with either previously untreated advanced Hodgkin's disease (HD) or with relapsed disease were treated with an intensive weekly chemotherapy regimen (ChlOPhEPP-B) in which the myelosuppressive combinations of epirubicin and chlorambucil, and procarbazine and etoposide alternated at two-week interv...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.2900100604

    authors: Smith GM,Wright D,Child JA,Simmons AV,Norfolk DR,Barnard DL,Parker D,Parapia L

    更新日期:1992-11-01 00:00:00

  • Research progress on exosomes derived from mesenchymal stem cells in hematological malignancies.

    abstract::Mesenchymal stem cells (MSCs) are a subset of multifunctional stem cells with self-renewal and multidirectional differentiation properties that play a pivotal role in tumor progression. MSCs are reported to exert biological functions by secreting specialized vesicles, known as exosomes, with tumor cells. Exosomes part...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2793

    authors: Lyu T,Zhang B,Li M,Jiao X,Song Y

    更新日期:2020-08-27 00:00:00